TrovaGene, Inc.
11055 Flintkote Avenue
San Diego
California
92121
United States
Tel: 858-952-7570
Website: http://www.trovagene.com/
About TrovaGene, Inc.
We are a clinical stage precision medicine biotechnology company developing oncology therapeutics for hematologic and solid tumor cancers. Beginning with our lead drug candidate PCM-075, a Polo-like Kinase 1 (PLK1) Inhibitor, we are on a journey to develop new treatment options to help transform cancer care.
PCM-075 is the first PLK1 inhibitor of its kind to enter clinical trials. Now with the FDA’s granting of orphan drug designation for PCM-075 to treat patients with Acute Myeloid Leukemia (AML), and initiation of our Phase 1b/2 clinical trial, we are moving forward with our clinical development program.
We optimize drug development by leveraging our significant experience and expertise in biomarker and Precision Cancer Medicine® (PCM) technology to address the need for new therapeutic options to treat hematologic and solid tumor cancers.
Stock Symbol: TROV
Stock Exchange: NASDAQ
293 articles about TrovaGene, Inc.
-
Trovagene Announces First Quarter 2020 Results and Highlights
5/7/2020
Trovagene, Inc., a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, announced company highlights and financial results for the first quarter ended March 31, 2020.
-
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
5/6/2020
- New corporate name, Cardiff Oncology, reflects the Company's mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients - Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and CEO to Executive Chairman and Dr. Mark Erlander will assume the role of CEO - Changes mark an important milestone in the Company's evolution and advancing development of onvansertib in cancer indications with the greatest medic
-
Onvansertib Trial in KRAS-Mutated Colorectal Cancer Demonstrates Consistent Tumor Regression Across KRAS Mutation Subtypes and Durable Response
4/28/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal cancer, prostate cancer and leukemia, today announced new positive results from its ongoing Phase 1b/2 clinical trial of onvansertib in combination with FOLFIRI and Avastin® (bevacizumab
-
Trovagene Expands Board with Addition of Three Industry Leaders - James Armitage, MD, Lâle White, and Gary Pace, PhD
4/22/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including colorectal, prostate and leukemia, today announced the election of three new independent Directors to its Board of Directors; Dr. James Armitage , Ms. Lâl
-
Trovagene to Present at the 19th Annual Needham Healthcare Conference
4/8/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate and leukemia, today announced it will be presenting at the 19th Annual Needham Healthcare Conference at 3:30
-
Trovagene Announces Acceptance of Phase 1b/2 KRAS-Mutated Metastatic Colorectal Cancer (mCRC) Trial Abstract for Presentation at the 2020 ASCO Annual Meeting
4/1/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, announced today that its Phase 1b /2 clinical trial of onvansertib in combination with standard-of-care FOLFIRI/Avastin® (bevacizumab) for second-line t
-
Trovagene Announces Three New Nominees for Election to Board of Directors
3/5/2020
Nominees bring extensive expertise in the fields of oncology drug development and commercialization, biopharmaceutical company financing and strategic operations
-
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
2/27/2020
Trovagene, Inc. (Nasdaq: TROV), today announced company highlights and financial results for the fourth quarter and full-year ended December 31, 2019.
-
Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients
2/13/2020
Trovagene, Inc. (Nasdaq: TROV), today announced positive data from its ongoing Phase 2 trial of onvansertib in combination with Zytiga® (abiraterone – Johnson & Johnson)/prednisone, all administered orally, for the treatment of patients with Zytiga®-resistant metastatic castration-resistant prostate cancer (mCRPC)
-
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
2/5/2020
Trovagene, Inc. (Nasdaq: TROV), today announced that a poster featuring efficacy data from its Phase 2 study in metastatic castrate-resistant prostate cancer (mCRPC), will be presented on Thursday, February 13th, 2020 at the American Society for Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium in San Francisco.
-
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
1/29/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, announced today that it has received approximately $1.45 million in proceeds from holders exercising common stock purchase warrants at an exercise price of $1.56 per share.
-
Onvasertib Demonstrates Effectiveness as Pan-KRAS Inhibitor with Confirmed Tumor Regression and Clinical Benefit Achieved in KRAS-Mutated mCRC Patients
1/27/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company targeting cancers that are both highly prevalent and in need of new effective treatment options including colorectal, prostate and acute myeloid leukemia, today announced positive data from an ongoing Phase 1b/2 clinical trial of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC).
-
Trovagene to Present New Clinical Data for Onvansertib in Metastatic KRAS-Mutated Colorectal Cancer at ASCO 2020 Gastrointestinal Cancers Symposium
1/21/2020
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, today announced that a poster featuring safety and efficacy data from its Phase 1b/2 study in metastatic KRAS-mutated colorectal cancer (mCRC), will be presented on Saturday, January 25th, 2020
-
Efficacy, Durability of Response and Safety of Onvansertib Demonstrated in Completed Phase 1b Trial in AML Patients Presented in Oral Session at ASH
12/9/2019
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today announced the presentation of final results from the Company's Phase 1b study of onvansertib in patients with relapsed/refractory acute myeloid leukemia (AML)
-
Trovagene Announces Data Showing Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia (AML)
12/4/2019
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including leukemia, prostate and colorectal, today announced new in-vitro and in-vivo data suggesting that onvansertib may provide a new therapeutic option for patients who develop resistance to frontline treatment with venetoclax.
-
Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®
11/14/2019
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including prostate, colorectal and leukemia, today announced new positive data from its Phase 2 trial evaluating onvansertib in combination with Zytiga®
-
Trovagene Announces Third Quarter 2019 Results and Highlights
11/7/2019
Trovagene, Inc., a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division for the treatment of various cancers including prostate, colorectal and leukemia, announced company highlights and financial results for the third quarter ended September 30, 2019.
-
Trovagene Announces Data from Acute Myeloid Leukemia (AML) Phase 1b/2 Trial of Onvansertib Chosen for Oral Presentation at ASH 2019 Annual Meeting
11/6/2019
Results from completed Phase 1b and ongoing Phase 2 trial of onvansertib in relapsed/refractory AML to be presented in oral session
-
Trovagene Announces $5.0 Million Private Placement Priced At-the-Market
10/25/2019
Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today announced that it has entered into definitive agreements with institutional investors for the sale of 2,756,340 shares of common stock
-
Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer
10/22/2019
Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5%